APA (7th ed.) Citation

SE, N., M, H., T, Y., H, M., T, O., K, W., . . . N, M. (2025). Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2- advanced breast cancer in the first-or second-line setting: A multicenter observational study (P-BRIDGE study). Breast cancer (Tokyo, Japan), 32(4), 705. https://doi.org/10.1007/s12282-025-01689-4

Chicago Style (17th ed.) Citation

SE, Nagai, et al. "Overall Survival of Palbociclib Plus Endocrine Therapy in Japanese Patients with HR+/HER2- Advanced Breast Cancer in the First-or Second-line Setting: A Multicenter Observational Study (P-BRIDGE Study)." Breast Cancer (Tokyo, Japan) 32, no. 4 (2025): 705. https://doi.org/10.1007/s12282-025-01689-4.

MLA (9th ed.) Citation

SE, Nagai, et al. "Overall Survival of Palbociclib Plus Endocrine Therapy in Japanese Patients with HR+/HER2- Advanced Breast Cancer in the First-or Second-line Setting: A Multicenter Observational Study (P-BRIDGE Study)." Breast Cancer (Tokyo, Japan), vol. 32, no. 4, 2025, p. 705, https://doi.org/10.1007/s12282-025-01689-4.